Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2025-12-28 @ 1:05 PM
Study NCT ID:
NCT00086203
Status:
COMPLETED
Last Update Posted:
2015-03-25
First Post:
2004-06-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Point Therapeutics
Organization:
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2006-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Detailed Description:
Completion date provided represents the completion date of the grant per OOPD records
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| FD-R-003021-01 | None | None | View |